Folitixorin - Isofol

Drug Profile

Folitixorin - Isofol

Alternative Names: 5-10-Methylenetetrahydrofolate; 6R-MTHF; [6R] 5,10-methylenetetrahydrofolate; ISO-901; Methylenetetrahydrofolate - Isofol; Modufolin; Modulfolin

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Merck Eprova
  • Developer Isofol Medical
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic-acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Folic acid deficiency; Rectal cancer

Most Recent Events

  • 05 Jul 2017 Isofol Medical plans a phase I trial in Healthy volunteers (NCT03203564)
  • 04 Jul 2017 Isofol Medical initiates a phase I trial in Healthy volunteers in Sweden (NCT03203564)
  • 22 Jun 2017 Phase-I/II clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease) in Denmark (IV) (NCT02244632)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top